New Opportunity for Early Protection against Enzootic Pneumonia
A revised licence for the vaccine Suvaxyn™ MH-One will provide a new opportunity for pig producers to extend protection against Mycoplasma hyopneumoniae.
The vaccine is now approved for use from seven days of age with a two-week onset of immunity, which means that piglets can be protected by three weeks of age when they are commonly already infected with M. hyo. Duration of immunity extends well beyond the average UK pig slaughter age of 176 days.
“This is a significant step forward, recognising the full efficacy of the Suvaxyn™ MH-One vaccine against enzootic pneumonia,” said Nigel Lodge, National Veterinary Manager for Zoetis in the UK. “Trials have confirmed that use of Suvaxyn™ MH-One at seven days reduces lung lesions - even in the presence of maternally derived antibodies.”
“The vaccine, which adds to our large and growing pig vaccine and product portfolio, also benefits from using adjuvants carbopol and squalane.”
The performance gains from early protection are shown in a field trial with 240 pigs injected at one week of age which showed significantly higher average daily weight gain, providing nearly 5 kg extra weight over the study period to 166 days.
The Zoetis portfolio of pig vaccines now offers protection against M.hyo, porcine circovirus, parasuis, parvo virus, erysipelas and E. coli, with a broad range of oral and injectable antibiotics.
